Alpha Emitter Market Report 2026

Alpha Emitter Market Overview

• Alpha Emitter market size has reached to $1.61 billion in 2025 • Expected to grow to $4.6 billion in 2030 at a compound annual growth rate (CAGR) of 23.3% • Growth Driver: Growth Of The Alpha Emitter Market Amid Rising Cancer Rates • Market Trend: Innovative Cyclotron-Based Production Of Alpha-Emitting Radionuclides • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Alpha Emitter Market?

An alpha emitter is a type of radioactive substance that releases alpha particles during radioactive decay. It includes elements, such as uranium, radium, and plutonium, that undergo alpha decay as part of their natural radioactive processes. Alpha emitters play a significant role in medical treatments, especially cancer therapy, and in various technological applications such as smoke detectors and space exploration. The main types of radionuclides of alpha emitters are radium, actinium, lead, bismuth, and others. Radium is a radioactive element used in medical treatments and diagnostic procedures. The source is natural sources, artificially produced sources, and others, and applications are pancreatic cancer, ovarian cancer, prostate cancer, lymphoma, melanoma, bone metastasis, and others. It is used by various end-users such as hospitals, medical research institutions, and others.

What Is The Alpha Emitter Market Growth Forecast?

The alpha emitter market size is expected to see exponential growth in the next few years. It will grow to $4.6 billion in 2030 at a compound annual growth rate (CAGR) of 23.3%. The growth in the forecast period can be attributed to development of artificial radionuclide production facilities, rising investment in oncology treatments, increasing adoption in bone metastasis and prostate cancer therapies, advancement in targeted alpha therapy technologies, expanding medical research applications. Major trends in the forecast period include rising adoption of alpha-emitter-based cancer therapies, increased research in radionuclide production and isolation, growth in artificially produced alpha emitters, expansion of therapeutic applications beyond oncology, enhanced focus on safety and regulatory compliance for handling radioactive materials.

Global Alpha Emitter Market Segmentation

1) By Type Of Radionuclide: Radium, Actinium, Lead, Bismuth, Other Types Of Radionuclides 2) By Source: Natural Sources, Artificially Produced Sources, Other Sources 3) By Application: Pancreatic Cancer, Ovarian Cancer, Prostate Cancer, Lymphoma, Melanoma, Bone Metastasis, Other Applications 4) By End-User: Hospitals, Medical Research Institutions, Other End-Users Subsegments: 1) By Radium: Radium-223, Radium-226, Radium-228 2) By Actinium: Actinium-227, Actinium-225 3) By Lead: Lead-210, Lead-212 4) By Bismuth: Bismuth-213, Bismuth-212 5) By Other Types of Radionuclides: Thorium, Polonium, Francium

What Is The Driver Of The Alpha Emitter Market?

The increasing prevalence of cancer is expected to propel the growth of the alpha emitter market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body, which can form tumors and invade surrounding tissues. The prevalence of cancer is due to factors such as aging populations, environmental exposures, lifestyle changes, and improved detection methods. Alpha emitters are used in cancer treatment to target and destroy tumor cells with high precision while minimizing damage to surrounding healthy tissues. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the alpha emitter industry.

Key Players In The Global Alpha Emitter Market

Major companies operating in the alpha emitter market are Bayer AG, Lantheus Holdings Inc., Curium Pharma, Eckert & Ziegler BEBIG GmbH, Telix Pharmaceuticals Limited, NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, International Isotopes Inc., IBA Radiopharma Solutions, Orano Med LLC, Actinium Pharmaceuticals Inc., Clarity Pharmaceuticals Ltd., RadioMedix Inc., Nordic Nanovector ASA, TAE Life Sciences, Fusion Pharmaceuticals Inc., Alpha Tau Medical Ltd., Alpha‑9 Oncology, Aktis Oncology, Abdera Therapeutics, Oncoinvent ASA, Theragnostics Ltd., ARICEUM Therapeutics, Sirius Medical Systems B.V.

Global Alpha Emitter Market Trends and Insights

Major companies operating in the alpha-emitter market are focusing on investing in innovative solutions, such as alpha-emitting radionuclides using cyclotrons, to gain a competitive edge. Alpha-emitting radionuclides produced using cyclotrons are radioactive isotopes that release alpha particles during decay, generated by accelerating charged particles to high energies in a cyclotron. For instance, in April 2023, Ionetix, a US-based cyclotron and technology company, produced its first alpha-emitting radionuclide, Astatine-211 (At-211), at its newly established Alpha Isotope Manufacturing facility in Lansing, Michigan. This facility is noteworthy for being the first in the U.S. dedicated solely to producing alpha-emitting radionuclides using cyclotron technology. The production was enabled by commissioning a 30 MeV cyclotron, specifically designed to accelerate alpha particles for the high-yield generation of At-211 and Actinium-225 (Ac-225).

What Are Latest Mergers And Acquisitions In The Alpha Emitter Market?

In February 2024, Bristol-Myers Squibb Co. (BMS), a US-based biopharmaceutical company, acquired RayzeBio, Inc. for $4.1 billion. With this acquisition, Bristol-Myers Squibb Co. (BMS) enhances its oncology portfolio by incorporating innovative radiopharmaceutical therapies, specifically targeted alpha-emitter treatments. RayzeBio Inc. is a US-based provider of alpha emitter.

Regional Outlook

North America was the largest region in the alpha emitter market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Alpha Emitter Market?

The alpha emitter market consists of sales of Plutonium-238 (Pu-238), Thorium-227 (Th-227), Polonium-210 (Po-210), and Americium-241 (Am-241). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.